Biocept (NASDAQ: BIOC) and Cancer Genetics (NASDAQ:CGIX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability and valuation.
Volatility & Risk
Biocept has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500. Comparatively, Cancer Genetics has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500.
Institutional and Insider Ownership
7.6% of Biocept shares are held by institutional investors. Comparatively, 17.2% of Cancer Genetics shares are held by institutional investors. 7.7% of Biocept shares are held by insiders. Comparatively, 21.3% of Cancer Genetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This table compares Biocept and Cancer Genetics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Biocept and Cancer Genetics’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Biocept||$5.07 million||2.45||-$21.61 million||($0.79)||-0.23|
|Cancer Genetics||$29.12 million||0.88||-$20.88 million||($0.79)||-1.17|
Cancer Genetics has higher revenue and earnings than Biocept. Cancer Genetics is trading at a lower price-to-earnings ratio than Biocept, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent ratings and recommmendations for Biocept and Cancer Genetics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Biocept presently has a consensus target price of $1.25, suggesting a potential upside of 586.81%. Cancer Genetics has a consensus target price of $6.00, suggesting a potential upside of 548.65%. Given Biocept’s stronger consensus rating and higher probable upside, equities analysts clearly believe Biocept is more favorable than Cancer Genetics.
Cancer Genetics beats Biocept on 7 of the 13 factors compared between the two stocks.
Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreatic biliary cancer, and ovarian cancer. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.
About Cancer Genetics
Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, India, and China. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. The company's clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management. Its biopharma services offer companies with customized solutions for patient stratification and treatment selection through a suite of molecular- and biomarker-based testing services, customized assay development, and trial design consultation. The company's discovery services provide the tools and testing methods for companies and researchers to identify new molecular-based biomarkers for disease. It serves hospitals, cancer centers, clinics, academic institutions, and government-sponsored research institutions, as well as pharmaceutical and biotech companies performing clinical trials. The company collaborates with oncology centers and community-based hospitals to develop its proprietary diagnostic tests. Cancer Genetics, Inc. was founded in 1999 and is based in Rutherford, New Jersey.
Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with MarketBeat.com's FREE daily email newsletter.